SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-041426
Filing Date
2021-03-25
Accepted
2021-03-25 14:14:10
Documents
2
Period of Report
2021-03-16

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2110920-6_3seq1.html 3  
1 OWNERSHIP DOCUMENT tm2110920-6_3seq1.xml 3 3112
2 POWER OF ATTORNEY tm2110920d6_ex24-1.htm EX-24.1 7226
  Complete submission text file 0001104659-21-041426.txt   11929
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Issuer) CIK: 0001534248 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O INNOVATE BIOPHARMACEUTICALS, INC. 8480 HONEYCUTT ROAD, SUITE 120 RALEIGH NC 27615
Business Address
Darvish Nissim (Reporting) CIK: 0001793602 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38807 | Film No.: 21771820